ADVERTISEMENT

84-Yr-Old Covid Patient Treated With Antibody Cocktail, Discharged

Published
Coronavirus
2 min read
84-Yr-Old Covid Patient Treated With Antibody Cocktail, Discharged

An 84-year-old Covid patient, Mohabbat Singh, became the first patient in India to receive monoclonal antibody therapy at the Medanta Hospital in Gurugram.

The patient with multiple comorbidities was discharged from the hospital on Wednesday, 26 May, a day after he was administered the jab.

“We are glad to have access to monoclonal antibody therapy in India now. This fast and effective treatment for Covid-19 will save patients at highest risk from falling critically ill, getting hospitalized or possibly dying of complications from Covid-19. We look forward to serving our patients with this therapy and saving more lives.”
Naresh Trehan, Chairman and Managing Director, Medanta
ADVERTISEMENT

This therapy increases the immune system's ability to fight off viruses and other harmful pathogens. A similar antibody cocktail was given to former US President Donald Trump when he had tested positive for Covid-19 last year.

Satya Prakash Yadav, Director, Pediatric Hematology Oncology & Bone Marrow Transplant, Medanta Hospital, tweeted, "Finally, monoclonal antibodies cocktail to treat Covid-19 available in market and a first patient to get it in Medanta is an 84-year-old gentleman with Covid-19. Let's hope it helps cure more patients with Covid-19."

“This drug is useful for those aged 60 years (or more) with mild to moderate Covid symptoms. Manufactured by CIPLA, the price of each dose is Rs 59,000. One dose is usually enough.”
Satya Prakash Yadav, Director, Pediatric Hematology Oncology & Bone Marrow Transplant, Medanta Hospital

The antibody combination of Casirivimab and Imdevimab now available in India is a cutting-edge treatment that will provide protection to Covid-19 positive patients with mild or moderate symptoms before they deteriorate further or require hospitalisation, the hospital statement said.

ADVERTISEMENT

"This FDA-approved therapy demonstrated good efficacy in Phase 1/2 and Phase 3 studies by reducing Covid-19 related hospitalization and death by 70 per cent. Approved by the Drugs Controller General of India (DCGI), this single-dose infusion-based treatment can be provided on an outpatient or day care basis and marks a dramatic shift in Covid-19 care in India," it said.

(This story was published from a syndicated feed. Only the headline and picture has been edited by FIT)

(This story was auto-published from a syndicated feed. No part of the story has been edited by The Quint.)

(The Quint is available on Telegram. For handpicked stories every day, subscribe to us on Telegram)

We'll get through this! Meanwhile, here's all you need to know about the Coronavirus outbreak to keep yourself safe, informed, and updated.

Liked this story? We'll send you more. Subscribe to The Quint's newsletter and get selected stories delivered to your inbox every day. Click to get started.

The Quint is available on Telegram & WhatsApp too, click to join.

Read and Breaking News at the Quint, browse for more from fit and coronavirus

Topics:  Old Age   covid 19   antibody coronavirus 

ADVERTISEMENT
Speaking truth to power requires allies like you.
Become a Quint Insider
25
100
200

or more

PREMIUM

3 months
12 months
12 months
Check Insider Benefits
Read More
ADVERTISEMENT
Stay Updated

Subscribe To Our Daily Newsletter And Get News Delivered Straight To Your Inbox.

Join over 120,000 subscribers!
ADVERTISEMENT
More News
×
×